AZ’ Tagrisso offers sustained benefit in lung cancer

16th April 2018 Uncategorised 0

AstraZeneca says that the “unprecedented progression-free survival benefit” of Tagrisso when used as a first line treatment for lung cancer is sustained through subsequent lines of therapy.

More: AZ’ Tagrisso offers sustained benefit in lung cancer
Source: News